<DOC>
	<DOCNO>NCT00139386</DOCNO>
	<brief_summary>Candesartan effective prevent cardiovascular event patient without restenosis coronary angioplasty . Therefore , investigator hypothesize candesartan drug-eluting stent ( DES ) implantation also effective prevent cardiovascular event . The purpose study investigate whether angiotensin II receptor blocker , candesartan , effective reduce incidence cardiovascular event drug-eluting stent implantation .</brief_summary>
	<brief_title>Candesartan Prevention Cardiovascular Events After Cypher Taxus Coronary Stenting ( 4C ) Trial</brief_title>
	<detailed_description>It report low-dose angiotensin II receptor blocker , candesartan , effective prevent cardiovascular event patient coronary artery disease treat coronary angioplasty ( Am Heart J 146 : E20 , 2003 ) . In study , patient without significant coronary stenosis follow-up angiography 6 month intervention randomly assign candesartan group ( baseline treatment plus candesartan 4 mg/d ) control group ( baseline treatment alone ) . It well known patient treat drug-eluting stent ( DES ) low restenosis rate compare bare metal stent . Therefore , hypothesize candesartan start immediately DES implantation effective prevent cardiovascular event . The primary endpoint composite cause death cardiovascular event ( nonfatal myocardial infarction , recurrent symptomatic myocardial ischemia , congestive heart failure , stroke ) . The secondary endpoint target lesion revascularization , binary restenosis , newly onset diabetes newly onset atrial fibrillation . Patient population need prove hypothesis estimate 1,130 case total ( 565 case group ) . We set parameter need calculate number study patient follow ; drop rate 10 % , event rate primary end point 3 year 20 % , risk reduction rate bring candesartan 25 % , statistical power 90 % two-sided significance level 0.05 . We assume event rate study conduct prove effect statin PCI Japan name MUSASHI-PCI . Also risk reduction rate two major RCTs candesartan conduct Japan name Ogaki HIJ-CREATE study . In Ogaki study , risk reduction rate candesartan 52 % . However , stent use study BMS survive restenosis . The risk reduction present study lower high onset rate stent thrombosis regard DES . Furthermore , risk reduction rate candesartan Japanese 11 % report HIJ-CREATE . The ACE-I usage rate almost 70 % control subject HIJ-CREATE . In present study , ACE-I administer less frequently low 30 % . Therefore , assume risk reduction rate candesartan present study could higher . Considering various factor together , reasonable risk reduction rate could 25 % .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>A . Patients hypertension , systolic blood pressure ( SBP ) = &gt; 140 and/or diastolic blood pressure ( DBP ) = &gt; 90 B . Patients symptomatic heart failure last least 4 week ( NYHA class = &gt; II ) , need continuous use diuretic C. Patients underwent coronary angioplasty drugeluting stent Eligible patient meet ( A B ) C. Severe renal hepatic disease Candidates coronary artery bypass grafting ( CABG ) Within 3 month CABG Allergic history candesartan Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Drug-eluting stent</keyword>
	<keyword>Candesartan</keyword>
	<keyword>Randomized control study</keyword>
	<keyword>Coronary Angioplasty</keyword>
</DOC>